Moreover, Abdel-Qadir et al. [19] used 11 different VEGF inhibitors, namely, aflibercept, axitinib, bevacizumab, cabozantinib, pazopanib, ramucirumab, regorafenib, sunitinib, sorafenib, vandetanib, and vatalanib, in patients with different types of cancer and reported a substantial increase in the risk of hypertension, cardiac ischemia, cardiac dysfunction, and arterial thromboembolism following anti-VEGF therapy. This evidence concerns the gene VEGFA and hypertensive disorder.